Neil A Klompas
Insider
First SEC filing: March 14, 2023 · Latest: March 14, 2023
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Dec. 19, 2025 | INM | A | 1,750 | · | · | 5,250 Direct | +50.00% | Acquired | (price as of 2026-10-02) |
| Oct. 17, 2025 | INM | A | 3,500 | · | · | 3,500 Direct | · | Acquired | (price as of 2026-10-02) |
| March 10, 2023 | ZYME | M | 2,708 | · | · | 2,709 Direct | -49.99% | Disposed | (price as of 2026-10-02) |
| March 10, 2023 | ZYME | M | 2,500 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| March 10, 2023 | ZYME | S | 2,977 | $7.83 | $23,310 | 17,032 Direct | -14.88% | Disposed | 221.2% (price as of 2026-10-02) |
| March 10, 2023 | ZYME | M | 2,708 | · | · | 20,009 Direct | +15.65% | Acquired | (price as of 2026-10-02) |
| March 10, 2023 | ZYME | M | 2,500 | · | · | 17,301 Direct | +16.89% | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2023 | ZYME | A | 58,500 | · | · | 58,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2023 | ZYME | A | 87,500 | · | · | 87,500 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Dec. 19, 2025 | INM | Employee Stock Option (Right to Buy) | Common shares | $1.29 | Dec. 18, 2030 | 1,750 | Acquired |
| Oct. 17, 2025 | INM | Employee Stock Option (Right to Buy) | Common shares | $2.10 | Oct. 16, 2030 | 3,500 | Acquired |
| March 10, 2023 | ZYME | Restricted Stock Unit | Common Stock | · | · | 2,708 | Disposed |
| March 10, 2023 | ZYME | Restricted Stock Unit | Common Stock | · | · | 2,500 | Disposed |
| Jan. 5, 2023 | ZYME | Restricted Stock Unit | Common Stock | · | · | 58,500 | Acquired |
| Jan. 5, 2023 | ZYME | Stock Option (Right to Buy) | Common Stock | $8.00 | Jan. 4, 2033 | 87,500 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $321,568 | · | · | · | · | · | $1,007,801 | $2,125,732 |
| 2022 | $503,795 | · | · | · | $330,699 | · | $23,878 | $1,808,408 |
| 2021 | $437,124 | · | · | · | · | · | $2,277 | $1,900,478 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.